Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.70 |
| ▸ | MGAM | O43451 | 1/20 | 0.70 |
| ▸ | SI | P14410 | 1/20 | 0.70 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15376 | 0.97 | — | — | |
| SCHEMBL30741390 | 0.97 | GAA (0.74) | GAAMGAMSIMGAM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7634629 | 0.95 | GAA (0.64) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL11097044 | 0.95 | GAA (0.70) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL13278763 | 0.95 | GAA (0.70) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL83057 | 0.95 | GAA (0.70) | GAAMGAMSIMGAM2ALDH1A1 | |
| Water SCHEMBL2811574 | 0.95 | GAA (0.70) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL3196229 | 0.95 | GAA (0.70) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL1068040 | 0.95 | GAA (0.70) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL3201235 | 0.95 | GAA (0.70) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024250573-A1 | REVERSE OSMOSIS MEMBRANE PREPARATION METHOD AND REVERSE OSMOSIS MEMBRANE PREPARED THEREBY | 沃顿科技股份有限公司 | 2024-12-12 | — | — | WO | claimed |
| CN-119098067-A | Method for producing reverse osmosis membrane and reverse osmosis membrane produced thereby | 沃顿科技股份有限公司 | 2024-12-10 | — | — | CN | claimed |
| CN-114432900-A | Preparation method of anti-pollution composite reverse osmosis membrane and anti-pollution composite reverse osmosis membrane prepared by same | 沃顿科技股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| WO-2024250573-A1 | REVERSE OSMOSIS MEMBRANE PREPARATION METHOD AND REVERSE OSMOSIS MEMBRANE PREPARED THEREBY | 沃顿科技股份有限公司 | 2024-12-12 | — | — | WO | disclosed |
| CN-114432900-B | Preparation method of anti-pollution composite reverse osmosis membrane and anti-pollution composite reverse osmosis membrane prepared by same | 沃顿科技股份有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-114432900-A | Preparation method of anti-pollution composite reverse osmosis membrane and anti-pollution composite reverse osmosis membrane prepared by same | 沃顿科技股份有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-109627202-B | Melatonin derivative and preparation method and application thereof | 李昱飞 | 2020-10-09 | — | — | CN | disclosed |
| US-10092584-B2 | Compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| CN-103958479-B | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof | 赛诺菲 | 2017-06-13 | — | — | CN | disclosed |
| WO-2017035360-A1 | COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-5468888-A | Lupane derivatives, their preparation and the pharmaceutical compositions which contain them | RHONE-POULENC RORER S.A. (FR) | 1995-11-21 | — | — | US | disclosed |
| US-4601889-A | ADSORPTION BY AN ACRYLIC POLYMER, URANIUM FROM SEAWATER | UBE INDUSTRIES, LTD. (JP) | 1986-07-22 | — | — | US | disclosed |
| US-4447431-A | VIRICIDES, ANTIINFLAMMATORY AND SUNCREEN AGENT | CIBA-GEIGY CORPORATION (US) | 1984-05-08 | — | — | US | disclosed |
| US-4305952-A | HAVING ANXIOLYTIC ACTION | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-12-15 | — | — | US | disclosed |
| US-4238506-A | SECONDARY OR TERTIARY AMIDE-SUBSTITUTED | BOEHRINGER MANNHEIM GMBH (DE) | 1980-12-09 | — | — | US | disclosed |
| US-4168312-A | Quinolone derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1979-09-18 | — | — | US | disclosed |
| US-4113871-A | HYPOGLYCEMICALLY AND HYPOLIPIDEMICALLY ACTIVE DERIVATIVES OF PHENYL-ALKANE-CARBOXYLIC ACIDS | BOEHRINGER MANNHEIM GMBH (DE) | 1978-09-12 | — | — | US | disclosed |
| US-RE28972-E | SEDATIVES, ANTICONVULSANTS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-09-21 | — | — | US | disclosed |
| US-3933886-A | HAIR DYE | HENKEL & CIE GMBH (DT) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10092584-B2 | Compounds for the treatment of medical disorders | CFD, TFPI, CFH | GAA 1837/4885MGAM 2509/4885SI 2143/4885 |
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | CFD, TFPI, CFH | GAA 1837/4885MGAM 2509/4885SI 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.